Infectious Disease Therapeutics Market Size to Hit USD 161.72 Billion by 2033

Infectious Disease Therapeutics Market Size, Share, Trends, Segmental Analysis By Drug Class (Antiviral Therapeutics [HIV Antiretrovirals, Hepatitis B and C Antivirals, Respiratory Antivirals, Other Antiviral Drugs], Antibiotic Therapeutics [Broad-Spectrum Antibiotics, Narrow-Spectrum/Targeted Antibiotics, Novel Antibiotic Classes], Antifungal Therapeutics [Azoles, Echinocandins, Polyenes, Novel Antifungal Agents], Antiparasitic Therapeutics [Antimalarials, Antiprotozoals, Antihelminthics], Other Drug Classes), By Indication (HIV/AIDS, Hepatitis B and C, Tuberculosis, Respiratory Infections, Sexually Transmitted Infections, Fungal Infections, Parasitic Infections, Other Indications), By Mode of Administration (Oral, Injectable/Intravenous, Topical, Other Modes), By Distribution Channel (Hospital Pharmacies, Retail and Community Pharmacies, Government and Public Health Programs, Online Pharmacies, Other Channels), By End User (Hospitals and Tertiary Care Centers, Specialty Infectious Disease Clinics, Community Clinics and Primary Care, Home Care Settings, Government Health Programs, Other End Users), By Region (North America [United States, Canada], Europe [Germany, United Kingdom, France, Italy, Spain, Rest of Europe], Asia Pacific [China, India, Japan, South Korea, Australia, Rest of Asia Pacific], Latin America [Brazil, Mexico, Rest of Latin America], Middle East & Africa [GCC Countries, South Africa, Rest of Middle East & Africa]), and Market Forecast, 2026 – 2033

  • Published: May, 2026
  • Report ID: 309
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Infectious Disease Therapeutics Market Size to Hit USD 161.72 Billion by 2033

(An Updated Version is Available)

1. Preface

  • 1.1 Report Description

  • 1.2 Research Scope & Assumptions

  • 1.3 Research Methodology & Data Sources

  • 1.4 List of Abbreviations

2. Executive Summary

  • 2.1 Market Snapshot

  • 2.2 Key Market Highlights

  • 2.3 Analyst Viewpoint & Key Findings

  • 2.4 Strategic Recommendations

3. Market Overview

  • 3.1 Market Definition & Scope

  • 3.2 Value Chain Analysis

    • 3.2.1 API & Raw Material Suppliers (Fermentation-Derived Compounds, Synthetic Intermediates, Biologic Substrates)

    • 3.2.2 Drug Discovery, Formulation & Pre-Clinical Development

    • 3.2.3 Clinical Trials, Regulatory Submission & Approval

    • 3.2.4 Manufacturing, Quality Control & GMP Compliance

    • 3.2.5 Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

    • 3.2.6 End-User Adoption (Hospitals, Specialty Clinics, Outpatient & Home Care Settings)

  • 3.3 Market Concentration & Characteristics

  • 3.4 Technology Roadmap & Innovation Pipeline

    • 3.4.1 Key Drug Technology Platforms

      • mRNA-Based Therapeutic & Vaccine Platforms (Moderna, BioNTech/Pfizer)

      • Long-Acting Injectable (LAI) Anti-Infective Formulations (Cabotegravir–Rilpivirine LAI, Lenacapavir)

      • Monoclonal Antibodies (mAbs) & Broadly Neutralizing Antibodies (bnAbs)

      • Direct-Acting Antiviral (DAA) Agents (HIV, HCV, HBV, Influenza)

      • Broad-Spectrum Antibacterials & Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations

      • Oral Small-Molecule Antivirals (Nirmatrelvir/Ritonavir — Paxlovid, Molnupiravir)

      • New-Generation Antifungals (Fosmanogepix, Rezafungin, Ibrexafungerp)

    • 3.4.2 Emerging & Complementary Technologies

      • AI-Driven Antimicrobial Drug Discovery Platforms (Eli Lilly–OpenAI, Locus Biosciences)

      • CRISPR & Phage-Based Precision Anti-Infective Therapies (SNIPR Biome LBP-EC01, BARDA-Funded Phase 2)

      • Host-Directed Therapies (HDTs) & Immunomodulatory Approaches for Drug-Resistant Infections

      • Nanomedicine & Targeted Drug Delivery Systems for Tuberculosis & Fungal Infections

      • 3D Bioprinting-Assisted Drug Formulation & In Vitro Infection Model Development

      • Stem Cell & Exosome-Based Immunotherapy for Chronic Infectious Disease Management

  • 3.5 Patent Analysis

    • 3.5.1 Patent Publication Trends in Anti-Infective Drug Molecules & Delivery Technologies

    • 3.5.2 Jurisdiction Analysis & Top Applicants (Pfizer, Gilead, GSK, Merck, Roche)

    • 3.5.3 Patent Cliff Analysis — Key Drug Expirations (2026–2033) & Generics Market Impact

  • 3.6 Pipeline Analysis

    • 3.6.1 Late-Stage Clinical Pipeline (Phase 3 Candidates by Disease Indication)

      • HIV: Lenacapavir Subcutaneous Twice-Yearly (Gilead, Phase 3 — PURPOSE 1 & 2)

      • Hepatitis D: Bulevirtide (Gilead/MYR GmbH) Long-Term Outcomes Data

      • Tuberculosis: JNJ-6640 PurF Inhibitor (MDR-TB), Navitoclax Adjunctive Therapy

      • Malaria: Triple Combination Regimens for Artemisinin-Resistant Strains (East Africa)

      • Gram-Negative Bacteria: Zosurabalpin (Roche — Phase 3, CRAB Infections, May 2025)

    • 3.6.2 Early-Stage Pipeline (Phase 1 & Phase 2 Candidates)

    • 3.6.3 Unmet Clinical Need by Disease Area & Regulatory Incentive Programs

  • 3.7 Regulatory Landscape & Compliance Framework

    • 3.7.1 U.S. FDA — Anti-Infective Drug Approval Frameworks

      • GAIN Act (Generating Antibiotic Incentives Now) — 5-Year Exclusivity Extension for Qualified Infectious Disease Products (QIDPs)

      • Breakthrough Therapy Designation (BTD) & Fast Track Designation for Priority Anti-Infectives

      • FDA 21 CFR Parts 314 & 601 — NDA, ANDA & BLA Approval Pathways

      • Real-Time Oncology Review (RTOR) & Adaptive Trial Design Approvals for Anti-Infectives

    • 3.7.2 European Medicines Agency (EMA) — PRIME Designation & Scientific Advice for AMR-Active Compounds

      • HERA (Health Emergency Preparedness and Response Authority) Stockpile Policies

      • EU Pharmaceutical Legislation Reform Impact on Anti-Infective Market Access

    • 3.7.3 Japan (PMDA) — Pharmaceutical and Medical Device Act Applicable to Anti-Infectives

    • 3.7.4 China (NMPA) — National Medical Products Administration NDA Approvals (32 Anti-Infective NDAs — 2024)

    • 3.7.5 India (CDSCO) — New Drugs & Clinical Trials Rules 2019 for Anti-Infective Therapeutics

    • 3.7.6 WHO Essential Medicines List (EML) & Global Procurement Frameworks (GAVI, PEPFAR, UNITAID)

    • 3.7.7 Key Regulatory Incentive Programs

      • Priority Review Vouchers (PRVs) for Neglected Tropical Disease Treatments

      • Advance Market Commitments (AMCs) for Vaccines & Anti-Infective Biologics

      • BARDA & CARB-X Funding Mechanisms for Priority Antimicrobial Development

  • 3.8 Pricing Analysis

    • 3.8.1 Brand vs. Generic Anti-Infective Drug Pricing Dynamics (U.S., Europe, Asia Pacific)

    • 3.8.2 Role of Voluntary Licensing & Tiered Pricing in Expanding Emerging Market Access

    • 3.8.3 Outcome-Based & Value-Based Pricing Models for Novel Anti-Infectives

  • 3.9 Reimbursement Landscape

    • 3.9.1 U.S. CMS & Commercial Insurer Reimbursement Policies for HIV, Hepatitis & Antifungal Therapies

    • 3.9.2 European National Health System (NHS) HTA Coverage for Anti-Infective Innovations

    • 3.9.3 Asia Pacific Government & Private Insurance Reimbursement for Infectious Disease Drugs

    • 3.9.4 Procurement Programs by Global Health Organizations (WHO, MSF, GFATM, UNITAID)

  • 3.10 Key Conferences & Industry Events (2026–2027)

    • 3.10.1 CROI (Conference on Retroviruses & Opportunistic Infections)

    • 3.10.2 ECCMID (European Congress of Clinical Microbiology & Infectious Diseases)

    • 3.10.3 IDWeek (Infectious Diseases Society of America — IDSA Annual Meeting)

    • 3.10.4 World Health Assembly (WHO WHA — AMR Agenda)

    • 3.10.5 ASM Microbe (American Society for Microbiology Annual Meeting)

  • 3.11 Unmet Needs in the Infectious Disease Therapeutics Market

    • 3.11.1 Novel Antibiotics Against Gram-Negative Drug-Resistant Pathogens (ESKAPE Pathogens)

    • 3.11.2 Affordable & Accessible Treatments for Neglected Tropical Diseases (NTDs)

    • 3.11.3 Long-Term Cure Strategies for Chronic Viral Infections (HIV Functional Cure, HBV Eradication)

    • 3.11.4 Antifungal Therapies for Invasive Fungal Infections in Immunocompromised Patients

  • 3.12 End-User Expectations & Key Buying Criteria

    • 3.12.1 Clinical Efficacy, Safety Profile & Real-World Outcome Data

    • 3.12.2 Ease of Administration, Patient Compliance & Long-Acting Formulation Availability

    • 3.12.3 Reimbursement Coverage & Formulary Positioning

    • 3.12.4 Supply Chain Reliability & Access to Essential Medicines

  • 3.13 AI & Digital Technology Integration in Infectious Disease Therapeutics

    • 3.13.1 AI-Powered Drug Target Identification & Compound Screening

    • 3.13.2 Digital Diagnostics & Telemedicine Supporting Infectious Disease Prescription Optimization

    • 3.13.3 AI-Driven Patient Adherence Monitoring for HIV, TB & Hepatitis Therapy

  • 3.14 Impact of Macroeconomic & Geopolitical Factors

    • 3.14.1 API Supply Chain Fragility & Geopolitics (67% of Antimicrobial APIs from India & China)

    • 3.14.2 Post-COVID-19 Pandemic Preparedness Investments Driving Anti-Infective R&D

    • 3.14.3 U.S.-China Geopolitical Tensions & Impact on API Import Policies

    • 3.14.4 Government Policies Supporting Universal Healthcare Access & AMR Stewardship

4. Market Dynamics

  • 4.1 Market Drivers

    • 4.1.1 Rising Global Prevalence of Infectious Diseases (Drug-Resistant TB, HIV, Malaria, Hepatitis, COVID-19, Influenza)

    • 4.1.2 Escalating Antimicrobial Resistance (AMR) Crisis Driving Demand for Novel Anti-Infective Agents

    • 4.1.3 Growing Awareness Initiatives by Governments & Global Health NGOs (WHO, PEPFAR, GFATM)

    • 4.1.4 Expanding Funding & R&D Investments in Anti-Infective Drug Discovery (BARDA, CARB-X, AMR Action Fund)

    • 4.1.5 Accelerated Regulatory Pathways Post-COVID-19 (FDA Fast Track, EMA PRIME, NMPA Priority Review)

    • 4.1.6 Long-Acting Injectable (LAI) Anti-Infectives Boosting Patient Adherence & Therapy Outcomes

    • 4.1.7 Increasing Strategic Collaborations, Acquisitions & Product Launches by Key Players

    • 4.1.8 Growing Burden of Chronic Infectious Diseases (TB, HIV, Hepatitis) Driving Sustained Demand

  • 4.2 Market Restraints

    • 4.2.1 Low Diagnosis & Treatment Penetration in Developing & Low-Income Regions

    • 4.2.2 Adverse Side Effects & Drug Toxicity Profiles Limiting Patient Compliance

    • 4.2.3 Antimicrobial Stewardship Programs Curbing Antibiotic Prescriptions (Up to 30% Usage Reduction)

    • 4.2.4 API Supply-Chain Fragility & Geopolitical Risks (India & China Concentration)

    • 4.2.5 Patent Expiry of Key Blockbuster Anti-Infective Drugs & Rising Generic Competition

  • 4.3 Market Opportunities

    • 4.3.1 AI-Driven Antimicrobial Discovery Platforms Shortening Drug Development Timelines

    • 4.3.2 Phage Therapy & CRISPR-Based Precision Anti-Infective Technologies

    • 4.3.3 Expanding Market Potential in Asia Pacific, Latin America & Sub-Saharan Africa

    • 4.3.4 Development of Combination Drug Therapies for Drug-Resistant TB, Malaria & HIV

    • 4.3.5 Strategic Partnerships with Global Health Organizations for Pandemic Preparedness

  • 4.4 Market Challenges

    • 4.4.1 Commercial Viability Challenges for Novel Antibiotics Under Stewardship-Restricted Use Models

    • 4.4.2 High Development Costs & Low Return on Investment for Neglected Tropical Disease Programs

  • 4.5 Porter's Five Forces Analysis

    • 4.5.1 Bargaining Power of Suppliers (API Manufacturers, Biotech Licensing Partners)

    • 4.5.2 Bargaining Power of Buyers (Government Procurement, Hospital Formularies, Insurance Payers)

    • 4.5.3 Threat of New Entrants (Regulatory & Capital Barriers; Biotech Disruptors via AI & Phage Platforms)

    • 4.5.4 Threat of Substitutes (Vaccines, Preventive Measures, Sanitation Programs)

    • 4.5.5 Intensity of Competitive Rivalry

  • 4.6 PESTLE Analysis

  • 4.7 Drivers Impact Analysis (% Contribution to CAGR Forecast)

  • 4.8 Restraints Impact Analysis (% Impact on CAGR Forecast)

5. Infectious Disease Therapeutics Market, By Disease Indication

  • 5.1 Overview & Market Share Analysis

  • 5.2 Viral Infections

    • 5.2.1 HIV / AIDS

      • Antiretroviral Therapy (ART) — Integrase Strand Transfer Inhibitors (INSTIs), NRTIs, NNRTIs, PIs

      • Long-Acting Injectable ART (Cabotegravir–Rilpivirine LAI; Lenacapavir Subcutaneous Twice-Yearly)

      • Broadly Neutralizing Antibodies (bnAbs) for HIV Prevention & Functional Cure Research

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.2.2 Hepatitis (A, B, C, D & E)

      • Hepatitis B: Direct-Acting Antivirals (Entecavir, Tenofovir) & Bulevirtide (Hepatitis D)

      • Hepatitis C: DAA Therapies (Sofosbuvir/Velpatasvir — Epclusa; Glecaprevir/Pibrentasvir — Mavyret)

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.2.3 Influenza & Respiratory Viral Infections

      • Neuraminidase Inhibitors (Oseltamivir — Tamiflu, Zanamivir)

      • Cap-Dependent Endonuclease Inhibitors (Baloxavir Marboxil — Xofluza)

      • COVID-19 Oral Antivirals (Nirmatrelvir/Ritonavir — Paxlovid; Molnupiravir — Lagevrio)

      • RSV Antivirals & Monoclonal Antibodies (Nirsevimab — Beyfortus)

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.2.4 Other Viral Infections

      • Ebola, Marburg, Dengue, Zika, Mpox Emerging Therapeutic Approaches

      • Market Size & Forecast

      • Key Trends & Applications

  • 5.3 Bacterial Infections

    • 5.3.1 Antibiotic-Sensitive Bacterial Infections (Community-Acquired Pneumonia, UTI, Skin & Soft Tissue)

      • Standard-of-Care Antibiotics (Penicillins, Cephalosporins, Fluoroquinolones, Macrolides)

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.3.2 Drug-Resistant / AMR Bacterial Infections (MDR-TB, MRSA, CRAB, CRE, ESBL Producers)

      • Next-Generation BL/BLI Combinations (Cefepime–Enmetazobactam, Ceftolozane–Tazobactam)

      • Novel Gram-Negative Agents (Zosurabalpin — Roche Phase 3, May 2025)

      • AI-Designed Resistance-Sparing Narrow-Spectrum Antibiotics

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.3.3 Tuberculosis

      • First-Line Regimens (HRZE — Isoniazid, Rifampicin, Pyrazinamide, Ethambutol)

      • MDR-TB & XDR-TB Regimens (BPaL — Bedaquiline, Pretomanid, Linezolid)

      • Investigational TB Drugs — JNJ-6640 (PurF Inhibitor), Navitoclax Adjunctive Therapy (April 2025)

      • Market Size & Forecast

      • Key Trends & Applications

  • 5.4 Fungal Infections

    • 5.4.1 Invasive Candidiasis & Aspergillosis

      • Existing Antifungals (Echinocandins, Azoles, Polyenes)

      • Next-Generation Antifungals (Fosmanogepix, Rezafungin, Ibrexafungerp, Olorofim)

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.4.2 Other Fungal Infections (Mucormycosis, Cryptococcal Meningitis, Histoplasmosis)

      • Market Size & Forecast

      • Key Trends & Applications

  • 5.5 Parasitic Infections

    • 5.5.1 Malaria

      • Artemisinin-Based Combination Therapies (ACTs) & Triple Combination Regimens (Artemisinin Resistance Response)

      • Tafenoquine (Krintafel) for Plasmodium vivax Radical Cure

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.5.2 Leishmaniasis, Schistosomiasis & Other Neglected Tropical Diseases (NTDs)

      • Market Size & Forecast

      • Key Trends & Applications

  • 5.6 Others

    • 5.6.1 Opportunistic Infections in Immunocompromised Patients (Transplant, Oncology, Autoimmune)

    • 5.6.2 Hospital-Acquired Infections (HAIs) — Clostridium difficile, MRSA Bacteremia

    • 5.6.3 Market Size & Forecast

6. Infectious Disease Therapeutics Market, By Drug Class

  • 6.1 Overview & Market Share Analysis

  • 6.2 Antibacterials

    • 6.2.1 Penicillins, Cephalosporins & Beta-Lactam/Beta-Lactamase Inhibitors

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.2.2 Fluoroquinolones & Macrolides

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.2.3 Glycopeptides & Oxazolidinones (Vancomycin, Dalbavancin, Tedizolid)

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.2.4 Others (Aminoglycosides, Tetracyclines, Polymyxins, Rifamycins)

      • Market Size & Forecast

      • Key Trends & Applications

  • 6.3 Antivirals

    • 6.3.1 HIV Antiretrovirals (INSTIs, NRTIs, NNRTIs, PIs, Attachment/Entry Inhibitors)

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.3.2 Hepatitis Antivirals (DAAs — NS3, NS5A, NS5B Inhibitors; HBV Antivirals)

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.3.3 Influenza, COVID-19 & Other Respiratory Virus Antivirals

      • Market Size & Forecast

      • Key Trends & Applications

  • 6.4 Antifungals

    • 6.4.1 Echinocandins, Azoles & Polyenes

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.4.2 Next-Generation Antifungals (Novel Mechanism-of-Action Compounds)

      • Market Size & Forecast

      • Key Trends & Applications

  • 6.5 Antiparasitic Drugs

    • 6.5.1 Antimalarials, Anthelmintics & Antiprotozoals

      • Market Size & Forecast

      • Key Trends & Applications

  • 6.6 Vaccines (Prophylactic & Therapeutic)

    • 6.6.1 mRNA Vaccines (Influenza, COVID-19, HIV Therapeutic — Phase 2 Trials)

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.6.2 Recombinant Protein & Vector-Based Vaccines (RSV, Pneumococcal, Meningococcal)

      • Market Size & Forecast

      • Key Trends & Applications

  • 6.7 Novel & Emerging Drug Classes

    • 6.7.1 Phage Therapy & CRISPR-Based Antimicrobials (LBP-EC01, SNIPR Biome)

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.7.2 Monoclonal Antibodies & Biologics (Nirsevimab, Ibalizumab, Leronlimab)

      • Market Size & Forecast

      • Key Trends & Applications

7. Infectious Disease Therapeutics Market, By Drug Type

  • 7.1 Overview & Market Share Analysis

  • 7.2 Small Molecules

    • 7.2.1 Market Size & Forecast

    • 7.2.2 Key Trends & Applications (Oral Outpatient Anti-Infectives, Generics Market)

  • 7.3 Biologics & Monoclonal Antibodies (mAbs)

    • 7.3.1 Market Size & Forecast

    • 7.3.2 Key Trends & Applications (Precision Anti-Infectives, Resistance-Sparing Biologics)

  • 7.4 Vaccines & Vaccine-Derived Therapeutics

    • 7.4.1 Market Size & Forecast

    • 7.4.2 Key Trends & Applications

8. Infectious Disease Therapeutics Market, By Route of Administration

  • 8.1 Overview & Market Share Analysis

  • 8.2 Oral

    • 8.2.1 Market Size & Forecast

    • 8.2.2 Key Trends & Applications (Standard Oral Antibiotics, Oral DAAs, Oral COVID-19 Antivirals)

  • 8.3 Injectable (IV, IM, Subcutaneous)

    • 8.3.1 Market Size & Forecast

    • 8.3.2 Key Trends & Applications (Long-Acting Injectables, Hospital-Administered Biologics)

  • 8.4 Transdermal & Inhalational

    • 8.4.1 Market Size & Forecast

    • 8.4.2 Key Trends & Applications (Inhaled Antifungals, Transdermal Anti-Parasitic Films)

9. Infectious Disease Therapeutics Market, By Distribution Channel

  • 9.1 Overview & Market Share Analysis

  • 9.2 Hospital Pharmacies

    • 9.2.1 Market Size & Forecast

    • 9.2.2 Key Trends & Demand Drivers (Stewardship Oversight, IV Anti-Infectives, ICU & Transplant Settings)

  • 9.3 Retail & Chain Pharmacies

    • 9.3.1 Market Size & Forecast

    • 9.3.2 Key Trends & Demand Drivers (OTC Antifungals, Oral Antivirals, Point-of-Care Test-and-Treat Models)

  • 9.4 Online Pharmacies

    • 9.4.1 Market Size & Forecast

    • 9.4.2 Key Trends & Demand Drivers (Telemedicine-Linked Antibiotic Prescribing, Direct-to-Patient Delivery)

10. Infectious Disease Therapeutics Market, By Region

  • 10.1 Overview & Market Share Analysis

  • 10.2 North America

    • 10.2.1 Market Size & Forecast

    • 10.2.2 United States

    • 10.2.3 Canada

    • 10.2.4 Mexico

  • 10.3 Europe

    • 10.3.1 Market Size & Forecast

    • 10.3.2 Germany

    • 10.3.3 United Kingdom

    • 10.3.4 France

    • 10.3.5 Italy

    • 10.3.6 Spain

    • 10.3.7 Denmark

    • 10.3.8 Sweden

    • 10.3.9 Norway

    • 10.3.10 Rest of Europe

  • 10.4 Asia Pacific

    • 10.4.1 Market Size & Forecast

    • 10.4.2 China

    • 10.4.3 Japan

    • 10.4.4 India

    • 10.4.5 Australia

    • 10.4.6 South Korea

    • 10.4.7 Thailand

    • 10.4.8 Rest of Asia Pacific

  • 10.5 Latin America

    • 10.5.1 Market Size & Forecast

    • 10.5.2 Brazil

    • 10.5.3 Argentina

    • 10.5.4 Rest of Latin America

  • 10.6 Middle East & Africa

    • 10.6.1 Market Size & Forecast

    • 10.6.2 Saudi Arabia

    • 10.6.3 United Arab Emirates

    • 10.6.4 South Africa

    • 10.6.5 Kuwait

    • 10.6.6 Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1 Market Share Analysis of Key Players

  • 11.2 Market Concentration & Competitive Characteristics (Moderately Fragmented — Top 6 Players Hold 60–70% Share)

  • 11.3 Company Evaluation Matrix — Key Players (2026)

    • 11.3.1 Stars (Dominant Full-Portfolio Global Biopharmaceutical Leaders)

    • 11.3.2 Emerging Leaders (High-Growth Specialty Anti-Infective Innovators)

    • 11.3.3 Pervasive Players (Generic & Biosimilar Anti-Infective Manufacturers)

    • 11.3.4 Participants (Early-Stage Biotech & Phage/CRISPR Therapy Developers)

  • 11.4 Competitive Benchmarking Matrix (by Disease Coverage, Drug Class, Technology & Geography)

  • 11.5 Heat Map Analysis

  • 11.6 Market Positioning of Key Players (2026)

  • 11.7 Strategic Developments & Recent Initiatives

    • 11.7.1 Mergers & Acquisitions

      • AbbVie Acquisition of Landos Biopharma (March 2024)

      • AstraZeneca Acquisition of Icosavax (USD 1.1 Bn — February 2024)

      • Pfizer–AbbVie Emblaveo Co-Development & FDA Approval (February 2025)

    • 11.7.2 Collaborations, Partnerships & Licensing Agreements

      • Eli Lilly–OpenAI AI Drug Discovery Partnership (USD 100 Million)

      • BARDA–ModeX Therapeutics COVID-19 Multispecific Antibody Program (USD 35 Million, 2024)

      • CARB-X 2025 Funding Round for Novel Gram-Negative Anti-Infectives

      • GSK–Fleming Initiative Commitment (USD 45 Million — AMR Drug Discovery, London)

    • 11.7.3 Product Launches & Regulatory Approvals

      • Roche Zosurabalpin Phase 3 for CRAB Infections (May 2025)

      • Gilead Bulevirtide 2-Year Sustained Virologic Response Data (May 2025)

      • SNIPR Biome First-in-Human CRISPR Antibiotic Dosing

      • Cefepime–Enmetazobactam FDA Approval (GAIN Act — Complicated UTIs)

    • 11.7.4 Expansions & Investments

      • Pfizer Vaccine Manufacturing Capacity Expansion (Asia Pacific, Latin America)

      • Gilead Sciences HIV & Hepatitis Portfolio Emerging Market Licensing Expansion

12. Company Profiles (The final report includes a complete list of companies)

  • 12.1 Pfizer Inc.

    • 12.1.1 Company Overview

    • 12.1.2 Financial Performance

    • 12.1.3 Product Portfolio

    • 12.1.4 Strategic Initiatives

    • 12.1.5 SWOT Analysis

  • 12.2 Gilead Sciences, Inc.

  • 12.3 Merck & Co., Inc.

  • 12.4 GlaxoSmithKline plc (GSK)

  • 12.5 F. Hoffmann-La Roche Ltd.

  • 12.6 AbbVie Inc.

  • 12.7 AstraZeneca plc

  • 12.8 Johnson & Johnson (Janssen Pharmaceuticals)

  • 12.9 Sanofi S.A.

  • 12.10 Novartis AG

  • 12.11 Bristol-Myers Squibb Company

  • 12.12 Boehringer Ingelheim International GmbH

  • 12.13 Cipla Limited

  • 12.14 Dr. Reddy's Laboratories Ltd.

  • 12.15 Viatris Inc.

13. Investment Analysis

  • 13.1 Investment Landscape Overview

  • 13.2 Mergers & Acquisitions Trend Analysis

  • 13.3 Venture Capital, Private Equity & Government Funding Trends in Infectious Disease Therapeutics

  • 13.4 Key Investment Opportunities by Region & Disease Indication

14. Future Market Outlook & Emerging Trends

  • 14.1 Trends & Disruptions Impacting Customers' Businesses

    • 14.1.1 Shifting Industry Paradigm from Volume-Driven to Resilience-Driven Anti-Infective Innovation

    • 14.1.2 Accelerating Transition from Small Molecules to Precision Biologics, Phage & CRISPR Platforms

  • 14.2 Emerging Technologies Reshaping Infectious Disease Therapeutics

    • 14.2.1 AI-Powered Drug Target Identification & Resistance Pathway Prediction Platforms

    • 14.2.2 CRISPR Genome-Edited & Phage-Based Precision Anti-Infective Therapies

    • 14.2.3 mRNA Therapeutic Platforms for HIV Functional Cure & Broad-Spectrum Antiviral Applications

    • 14.2.4 Long-Acting Injectable & Subcutaneous Anti-Infectives (Annual & Biannual Dosing Schedules)

    • 14.2.5 Nanotechnology-Based Drug Delivery for Targeted Anti-Infective Delivery (TB, Invasive Fungal)

    • 14.2.6 Host-Directed Therapies (HDTs) for Drug-Resistant TB, HIV & Systemic Fungal Infections

    • 14.2.7 Combination Anti-Infective + Immunotherapy Strategies for Chronic Viral Infection Eradication

    • 14.2.8 Microbiome-Sparing Precision Antibiotics Designed to Preserve Gut Flora During Treatment

    • 14.2.9 Digital Therapeutics, AI-Adherence Monitoring & Smart Pill Technologies for HIV & TB

    • 14.2.10 Reshoring & Regional API Manufacturing Strategies to Mitigate Supply Chain Geopolitical Risk

  • 14.3 Future Market Projections (2026–2033)

  • 14.4 Strategic Recommendations for Market Participants

15. Appendix

  • 15.1 Research Methodology

  • 15.2 Data Triangulation & Validation

  • 15.3 List of Tables & Figures

  • 15.4 List of Abbreviations & Acronyms

  • 15.5 About the Publisher

16. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.